Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms IDEA
- Sponsors Abbott Laboratories; AbbVie
- 20 Nov 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 05 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 23 Jan 2014 Planned End Date changed from 1 Dec 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.